Medical and Pediatric Oncology 1991-01-01

Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.

P J Stiff, D Sweet, L J Kilton, C M Johnson, B Muntean, R R Blough

Index: Med. Pediatr. Oncol. 19(2) , 126-8, (1991)

Full Text: HTML

Abstract

Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one patient for a febrile incident, and superficial phlebitis. The results were similar to those of previous studies, in that among the 13 patients evaluable for response (six previously untreated with chemotherapy) there were no responses.

Related Compounds

  • Bisantrene

Related Articles:

In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.

1990-01-01

[Haematologica 75(6) , 527-31, (1990)]

Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.

2014-04-29

[Clin. Cancer Res. 2(6) , 973-80, (1996)]

Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.

1998-01-20

[Bioorg. Med. Chem. Lett. 8(2) , 121-6, (1998)]

Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.

1990-08-01

[Invest. New Drugs 8(3) , 313-5, (1990)]

Bisantrene in relapsed and refractory acute myelogenous leukemia.

1993-02-01

[Leuk. Lymphoma 9(3) , 217-20, (1993)]

More Articles...